International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

The ISRS webinar series began in 2016. We have already delivered over 60 webinars on intracranial and body SRS and from experts around around the world.

A video replay of each past webinar is available to ISRS members.

Next Webinars

April 16, 2020

SRS/SRT of Atypical and Anaplastic Meningiomas by Elitsa ENCHEVA, MD, PhD, Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

The webinar will discuss: 1) the current WHO classification for meningioma and the incidence of the atypical and anaplastic meningioma and the treatment results according to it. 2) the treatment strategy for both atypical and anaplastic meningioma and the role of radiotherapy 3) the current evidence supporting EBRT, SRS and SRT implementation for atypical and anaplastic meninigiomas in adjuvant and recurrent settings

April 27, 2020

MR-Guided Radiotherapy: a Game Changer or all Hype? by Alison TREE, MD (Res)

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

MR-guided radiotherapy promises to revolutionise radiotherapy delivery. These systems bring the obvious benefits of improved soft-tissue definition, and the ability to monitor anatomy with cineMRI during beam-on. However, the more fundamental innovation is the ability to deliver daily adaptive replanning while the patient is on the bed, allowing us to, for the first time, adapt our radiation plan daily to account for anatomical changes. This has great potential, particularly in the ‘hard to treat’ cancers where dose escalation has previously been limited by proximity to OARs, and the need to cover a large margin for interfraction variability. Dr Tree will share the Royal Marsden/Institute of Cancer Research experience of MR-guided radiotherapy and suggest some areas where it will improve patient care in the future.

May 05, 2020

Leptomeningeal Metastases: an Overview of a Devastating Diagnosis by Hany SOLIMAN, MD, FRCPC

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

Leptomeningeal metastases is characterized by dissemination of cancer cells throughout the leptomeninges and/or cerebrospinal fluid. It is usually associated with a very poor prognosis. This webinar will review the incidence in different cancers, predictors of and varying patterns seen with leptomeningeal metastases in clinical practice. Novel therapies including targeted agents have shown some promise in improving outcomes and will be highlighted.

June 08, 2020

When is it Reasonable and Unreasonable to Consider Hypofractionation as Opposed to Single Session SRS? by Dade LUNSFORD, M.D., F.A.C.S., Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

In this webinar Professor Lunsford will provide his perspective on the role of single session vs multisession (or fractionation) for patients who are appropriately managed by stereotactic radiosurgery. He will emphasize the accumulated knowledge obtained over the last 50 years in more than 1.3 million patients who have had Leksell radiosurgery and the more than 1000 publications that define outcomes for single session procedures. In the face of the accumulated evidence the limited role for fractionation will be explored.